The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma-Reference-Cited by-同舟云学术

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma

Published:2017-05 Issue:5 Volume:12 Page:850-859
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Thapa Bibhusal,Salcedo Adriana,Lin Xihui,Walkiewicz Marzena,Murone Carmel,Ameratunga Malaka,Asadi Khashyar,Deb Siddhartha,Barnett Stephen Arthur,Knight Simon,Mitchell Paul,Watkins D. Neil,Boutros Paul C.,John Thomas

Funder

Lyall Watt’s Mesothelioma

Australian Postgraduate

Ontario Institute for Cancer Research

Terry Fox Research Institute

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

2. Targeting the vasculature: anti-angiogenesis agents for malignant mesothelioma;Chia;Expert Rev Anticancer Ther,2016

3. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial;Calabrò;Lancet Oncol,2013

4. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study;Calabrò;Lancet Respir Med,2015

5. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression;Hassan;J Clin Oncol,2016

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of first-line and salvage therapies for unresectable malignant mesothelioma: A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-06

2. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions;Archives of Pathology & Laboratory Medicine;2024-01-08

3. Malignant and borderline mesothelial tumors of the pleura;Practical Pulmonary Pathology;2024

4. Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy;Cancers;2023-12-10

5. Preoperative neutrophil-to-lymphocyte ratio correlates with PD-L1 expression in immune cells of patients with malignant pleural mesothelioma and predicts prognosis;Scientific Reports;2023-03-31